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Undesirable Implications of Disclosing Individual
Genetic Results to Research Participants
Leslie A. Meltzer, Georgetown University Law Center and Johns Hopkins Bloomberg School of Public Health

Ravitsky and Wilfond (2006) correctly highlight the need
for uniform guidelines to assist investigators and institutional review boards (IRBs) in determining whether
to disclose individual genetic results to research participants. However, their results-evaluation framework, like
other proposals that call for the disclosure of individual results to research participants (Partridge and Winer 2002;
Rothstein 2006; Shalowitz and Miller 2005), is troublesome for two related reasons. First, their justification for
disclosure rests on the mistaken view that principles of
beneficence, respect, reciprocity, and/or justice ethically
require researchers to offer participants individual genetic
results. Whereas these principles and others obligate physicians to share individually relevant results with patients
in the clinical care setting, they do not similarly obligate investigators to share such information with participants in the research setting. Second, because Ravitsky and
Wilfond’s proposal conflates the aims of clinical research
with those of clinical care, participants may suffer from a
therapeutic or diagnostic misconception (Clayton and Ross
2006), researchers may be inclined to overstate the benefits of enrollment, and institutional review boards (IRBs)
may face unforeseen difficulties in assessing trial risks and
benefits.
Beneficence, respect for persons, reciprocity, and justice
are important components of ethical research, but none
of these principles are violated or diminished when investigators do not share individual genetic results from
research. Beneficence requires investigators to maximize
possible benefits to participants and society at large while
minimizing possible harms. Whether a clinical trial meets
the requirement of beneficence is determined ab initio by
an IRB before any participants are enrolled. At this stage
of review, an IRB cannot weigh the possibility that some
participants may gain individually useful results from participation. There is no guarantee that any given trial will
produce such results. In contrast, if a study does generate individual information, it may apply only to participants with certain genomic characteristics. And even
in this case it is not possible to determine whether a
given participant will perceive the information as a benefit or harm once confronted with it. Because a clinical
trial must meet the requirements of beneficence regardless
of whether it returns individual research results, it cannot be the case that beneficence requires investigators to
offer results.
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Ravitsky and Wilfond (2006) may respond that failure to disclose genetic information that is of direct clinical
utility to participants violates nonmaleficence, the duty to
minimize harms in research. However, except in the very
rare circumstance in which failure to disclose individual
genetic information to a participant poses a certain and
near-immediate threat to morbidity (and thus should be
disclosed), nonmaleficence does not trigger disclosure. Investigators have a duty not to expose participants to undue
risk. This negative duty of nonmaleficence is quite different,
however, from any positive duty to promote participants’
interests, the activity that seems to motivate Ravitsky and
Wilfond’s proposal. They may reply that failure to offer
beneficial results is itself a harm, but this understanding of
harm as “failure to benefit” would, as previously noted, pose
intractable difficulties for IRBs assessing probable harmbenefit ratios for research trials (Parker 2006).
Ravitsky and Wilfond’s (2006) argument that respect
for persons requires disclosure is similarly mislaid. Respecting participants means treating human beings capable of self-determination as autonomous agents. It requires researchers to present prospective participants with
adequate information about a trial, to honor their voluntary decision about enrollment, and to accept participants’ decisions to withdraw from trials should they
so choose. But respect for persons does not require researchers to account for participant interests or preferences about disclosure of individual genetic research results
when designing a study. Investigators best respect participants as persons when they disclose the terms of the
research and allow people to choose whether to enroll.
This approach, rather than integrating participant preferences into research, is what The Belmont Report and
the Common Rule mean by respecting participant selfdetermination.
Just what Ravitsky and Wilfond (2006) envision when
they claim that reciprocity in research requires disclosure
is somewhat unclear. They contend that reciprocity requires researchers to consider the nature of their relationship with participants when deciding to disclose results,
paying particular attention to “the duration and the intensity of this relationship” (2006, 8). This approach to
reciprocity is somewhat more nuanced than the standard
call for participants to receive something from researchers
in exchange for participation. If researchers were to disclose
individual results to participants, then arguably the degree
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and nature of their relationship with participants should
factor into any decision about disclosure. But from the
standpoint of reciprocity, if participants receive anything
in exchange for participation (such as monetary compensation or aggregate study results), they all ought to receive
the same thing regardless of the duration or intensity of
their relationship with researchers, and they ought to receive it regardless of the trial’s success. In the case of
disclosing individual genetic results, however, the compensation is both uncertain and unlikely to be available to all
participants.
The final principle that Ravitsky and Wilfond (2006)
employ is justice. They argue that “justice requires balancing participants’ preferences against considerations of
prioritizing resources utilization in order to maximize the
benefits of research to society” (8). As I understand it, this
statement is less a justification for disclosing individual
results to participants than it is a recognition that doing
so may cause complicated trade-offs with other research
priorities. They do not contend that failing to disclose individual results violates justice per se, only that once we
enter the realm of disclosure, there are complex issues of
resource allocation. On this point, I agree. The resultsevaluation approach creates the very real possibility that
research participants in studies with larger budgets are more
likely to receive results than those in studies with less room
for such expenditures. Even within trials, it may become
difficult to treat participants equally over the duration of
the study.
Ravitsky and Wilfond’s (2006) justifications for their
approach suggest that they have fallen prey to the same
problem that plagues the autonomy-based approach: the
failure to distinguish between medical practice and clinical research. In the personal context of the physician–
patient relationship, fundamental ethical principles compel
physicians to share individual genetic results with patients.
In fact, failure to share such information in all but the
most exceptional circumstances is legally actionable because physicians are fiduciaries to their patients. This means
that physicians have not only an ethical, but also a legal
duty to act solely for the benefit of their patients (Morreim
2005).
In contrast, in the research setting, investigators are
not fiduciaries of participants. Their primary goal is not,
and indeed cannot be, to benefit any one participant. The
very distinction between research and clinical care rests on
the fact that research aims to produce generalizable knowledge for society at large, whereas clinical care aims to meet
individuals’ specific needs, interests, and preferences. This
distinction does not mean that participants in clinical trials gain no benefits from participation. Participants may,
for example, receive better care than they would receive
outside a trial or gain access to otherwise unaffordable
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medication. But the nature of research design—from
randomization to double blinding—betrays its overarching purpose: to yield scientifically accurate, generalizable
knowledge.
Ravitsky and Wilfond’s (2006) proposal breaks down
this important distinction between medical care and research by conflating the duties owed to patients with those
owed to participants. In addition to the rationale outlined
previously, there are two further reasons we should resist
this move. First, offering individualized information to research participants invites them, as well as researchers and
IRBs, into the therapeutic misconception, or what Clayton
and Ross (2006) term the “diagnostic misperception.” Both
terms capture the expectation that, under Ravitsky and
Wilfond’s proposal, participants will receive clinically relevant personal information just as they would in a physician–
patient relationship. This view is pernicious because people who otherwise would not enroll in research may choose
to do so in the hope of personal benefit, and researchers
may be inclined to overstate the benefits of participation.
Moreover, as discussed previously, IRBs may find it difficult to conduct a valid risk-benefit assessment of proposed
research.
The second reason for maintaining a dichotomy between clinical research and medical practice is to protect
research from the intrusion of unnecessary malpractice litigation. Investigators are not fiduciaries of research participants, and as such, do not presently have a legal obligation
to act in the best interests of participants (Morreim 2005).
If, however, researchers have an ethical duty to disclose individual research results, as Ravitsky and Wilfond (2006)
contend they do, then a court may be able to conclude
that investigators owe participants fiduciary duties. In the
abstract, this conclusion may seem like a matter of semantics, but if researchers become participant fiduciaries, their
ability to conduct research as we know it may drastically
change. 
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Disclosing Genetic Research Results: Examples
from Practice
Kelly E. Ormond, Northwestern University

Using examples from my own practice as a genetic counselor, I would like to provide a context for how the points
raised by Ravitsky and Wilfond (2006) and other peer commentators can be, and are, practically incorporated into
the practice of medical genetics. I applaud the authors for
their initiative to develop an objective approach that considers analytic and clinical utility, clinical validity, personal
meaning, and the relationship with investigators; this approach is critical because the typical defaults of disclosing results to all or none or allowing institutional review
board (IRB) discretion for disclosure lead to inconsistent
approaches that minimize opportunities for participant autonomy and values-based decisions about genetic research
results.
Although genetic testing is frequently discussed, it
is currently only available for approximately 1300 genetic conditions; approximately 25% of those conditions have only research genetic testing as an option
(www.geneclinics.org). In the early stages of genetic testing research, affected individuals and their families may be
recruited into research to identify genes that contribute
to a disease state. Once the causal gene(s) is identified,
it may still take years to translate from research to clinical testing; this process is even more difficult for rare
disorders for which laboratories may not wish to invest
time or resources to offer clinical testing. In practice, this
time line means that research genetic testing may be performed for essentially clinical purposes. When clinical testing is not yet available, families may believe that research
based genetic testing is the “only option” and participate
hoping researchers will identify the causal gene so that

30 ajob

future testing will become available; however, they may
also directly hope to gain information about the genetic
makeup of affected family members. As a clinician who
is often in the position of presenting research testing options to patients, I argue that, out of respect for subjects,
their autonomy, and the potential impact on their personal welfare, researchers should offer to disclose research
results to patients if one can obtain verifiable results to
which participants assign personal value, particularly when
the research setting is the only venue in which testing is
available.
These situations are less ethically challenging than the
scenarios in which genetic test results are obtained as
a component of a larger study. A clear statement about
intent to disclose results (or not) is an important part
of the informed consent process. I have had healthy patients referred who participated in a research study for
dementia that involved the assessment of apolipoprotein
status and who desired to learn their genetic results. I
have also worked with families who are contemplating
genetic research to help identify a cause for dementia
in deceased relatives, with the intent that predictive
testing could be made available to other yet unaffected family members if results were provided. Here,
medical management would not be altered, but families still reported high value in learning the genetic
information.
When helping families and patients consider the risks
and benefits of obtaining genetic test results, the “accuracy” of test results and the level of certainty about what
that will mean for them and their family are important.
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